Edwards Lifesciences (NYSE:EW) Stock Price Expected to Rise, Barclays Analyst Says

Key Points

• Barclays raised its price target on Edwards Lifesciences to $120 from $110 and maintained an “overweight” rating, implying 20.88% upside from the prior close.
• The company beat quarterly estimates, reporting EPS of $0.80 and revenue of $1.72 billion; revenue grew 10.5% year over year. Analysts’ average rating is “Moderate Buy,” with an average price target of $105.32.
• Growth prospects include strong demand for transcatheter therapies, but increasing TAVR competition could pressure market share or pricing, and analysts differ on how much trial results may expand the market.

Edwards Lifesciences (NYSE:EW - Get Free Report) had its target price raised by research analysts at Barclays from $110.00 to $120.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has an "overweight" rating on the medical research company's stock. Barclays's target price would indicate a potential upside of 20.88% from the stock's previous close.

EW has been the subject of a number of other reports. Piper Sandler reissued an "overweight" rating and set a $115.00 price objective (up from $101.00) on shares of Edwards Lifesciences in a research report on Thursday. Jefferies Financial Group lifted their price target on shares of Edwards Lifesciences from $102.00 to $105.00 and gave the stock a "buy" rating in a research note on Friday, July 24th. The Goldman Sachs Group boosted their price target on shares of Edwards Lifesciences from $98.00 to $102.00 and gave the stock a "buy" rating in a report on Tuesday, July 14th. Truist Financial set a $113.00 price objective on shares of Edwards Lifesciences and gave the company a "buy" rating in a research report on Wednesday. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Edwards Lifesciences in a report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average price target of $105.32.

Edwards Lifesciences Trading Down 0.1%

Shares of EW stock traded down $0.10 on Thursday, hitting $99.27. 5,229,963 shares of the stock traded hands, compared to its average volume of 4,512,299. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences has a twelve month low of $74.66 and a twelve month high of $104.17. The firm's 50-day moving average price is $88.48 and its two-hundred day moving average price is $85.61. The stock has a market capitalization of $57.16 billion, a PE ratio of 57.04, a PEG ratio of 2.49 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.06. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The company had revenue of $1.72 billion during the quarter, compared to analysts' expectations of $1.68 billion. During the same quarter last year, the firm earned $0.67 earnings per share. The firm's quarterly revenue was up 10.5% compared to the same quarter last year. As a group, analysts anticipate that Edwards Lifesciences will post 3.00 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 544 shares of Edwards Lifesciences stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the sale, the senior vice president owned 14,868 shares in the company, valued at approximately $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 619 shares of the business's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares of the company's stock, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,045 shares of company stock valued at $451,596 in the last ninety days. Insiders own 0.31% of the company's stock.

Institutional Trading of Edwards Lifesciences

Large investors have recently bought and sold shares of the business. Illinois Municipal Retirement Fund lifted its holdings in shares of Edwards Lifesciences by 15.7% during the third quarter. Illinois Municipal Retirement Fund now owns 46,772 shares of the medical research company's stock worth $4,037,000 after buying an additional 6,359 shares during the last quarter. Bahl & Gaynor LLC grew its stake in shares of Edwards Lifesciences by 87.3% in the third quarter. Bahl & Gaynor LLC now owns 9,547 shares of the medical research company's stock worth $824,000 after acquiring an additional 4,449 shares during the last quarter. AMG National Trust Bank grew its stake in shares of Edwards Lifesciences by 6.1% in the third quarter. AMG National Trust Bank now owns 80,054 shares of the medical research company's stock worth $6,910,000 after acquiring an additional 4,582 shares during the last quarter. Lido Advisors LLC increased its position in Edwards Lifesciences by 5.2% during the third quarter. Lido Advisors LLC now owns 34,192 shares of the medical research company's stock worth $2,951,000 after acquiring an additional 1,691 shares during the period. Finally, Csenge Advisory Group increased its position in Edwards Lifesciences by 127.8% during the third quarter. Csenge Advisory Group now owns 14,437 shares of the medical research company's stock worth $1,246,000 after acquiring an additional 8,099 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences News Roundup

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported third-quarter adjusted EPS of $0.80 and revenue of $1.72 billion, topping estimates. Sales grew 11.2% year over year, supported by 8.8% growth in TAVR and a 45.6% surge in transcatheter mitral and tricuspid therapies (TMTT). The company raised its full-year adjusted EPS outlook to $2.97–$3.05, reinforcing expectations for continued growth. Q3 earnings call highlights
• Positive Sentiment: New PROGRESS Trial results found TAVR performed better than active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure outcomes, fewer heart-failure hospitalizations and improved quality of life. The findings could support earlier use of the procedure; the company also expects procedure volumes to benefit from expanded Medicare reimbursement. PROGRESS Trial data
• Positive Sentiment: Several firms raised price targets after the results. Piper Sandler and BTIG set targets of $115, Baird upgraded EW to “outperform” with a $116 target, and JPMorgan raised its target to $120. These actions signal improved analyst expectations. JPMorgan price target change
• Negative Sentiment: Management cautioned that more competition is coming in TAVR, which could pressure market share or pricing. RBC also said the PROGRESS findings may not meaningfully expand the TAVR market, tempering expectations for the trial’s commercial impact. CEO comments on TAVR competition

About Edwards Lifesciences

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart's valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.